Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations

被引:0
作者
Coutinho, Anna D. [1 ]
Raju, Aditya D. [1 ]
Wang, Weijia [2 ]
Stafkey-Mailey, Dana [1 ]
Shetty, Sharash [2 ]
Sander, Stephen D. [2 ]
机构
[1] Xcenda LLC, Palm Harbor, FL USA
[2] Boehringer Ingelhe Pharmaceut Inc, Ridgefield, CT USA
关键词
Cardiovascular disease; hospitalization; healthcare resource utilization; healthcare costs; observational studies; HEART-DISEASE; ALL-CAUSE; OUTCOMES; MORTALITY; WOMEN; MEN; MELLITUS; FAILURE; RISK;
D O I
10.1080/03007995.2018.1434497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the incremental economic burden of type 2 diabetes in patients experiencing cardiovascular (CV) hospitalizations. Research design and methods: Adults with >= 1 CV hospitalization were identified using a US-based healthcare claims database from 1 July 2011 to 30 June 2014. Outcomes for patients surviving the index hospitalization were compared between patients with vs. without type 2 diabetes (cohorts were identified in the pre-index period). Subsequent CV hospitalizations were evaluated using Cox proportional hazards models. All-cause and CV-related healthcare resource utilization (HCRU) and costs captured on a per-patient per-month (PPPM) basis during a variable follow-up period were evaluated using appropriate multivariable regression models. Results: Of 316,207 patients with >= 1 CV hospitalization, 23% had comorbid type 2 diabetes. The mean age +/- SD was 62.6 +/- 12.3 years and 64.4% were male. During follow-up, the type 2 diabetes cohort had a 19% higher risk of subsequent CV hospitalizations compared to the non-type-2-diabetes cohort (p <.001). This difference in risk was highest in patients aged 35-44 years. Subsequent all-cause hospitalizations for the type 2 diabetes cohort were longer (mean length of stay, 6.7 vs. 6.3 days; p <.001), with higher total bed-days PPPM (mean, 0.52 vs. 0.43; p <.001), compared to the non-type-2-diabetes cohort. The type 2 diabetes cohort had a significantly higher incremental cost for both the index CV hospitalization (mean cost difference, $1046; p <.001) and all-cause costs PPPM following discharge (mean cost difference, $749; p < .001). Conclusions: Comorbid type 2 diabetes was associated with an increased risk of subsequent CV hospitalizations and higher costs and HCRU during the follow-up period.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 26 条
[1]   Introduction [J].
不详 .
DIABETES CARE, 2017, 40 :S1-S130
[2]  
[Anonymous], 2008, GUID IND DIAB MELL E
[3]   Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study [J].
Booth, Gillian L. ;
Kapral, Moira K. ;
Fung, Kinwah ;
Tu, Jack V. .
LANCET, 2006, 368 (9529) :29-36
[4]  
CDC, NAT DIAB STAT REP 20
[5]   Clinical Outcomes and Medication Adherence in Acute Coronary Syndrome Patients With and Without Type 2 Diabetes Mellitus: A Longitudinal Analysis 2006-2011 [J].
Cziraky, Mark J. ;
Reddy, Vanessa S. ;
Luthra, Rakesh ;
Xu, Yaping ;
Wilhelm, Kenneth ;
Power, Thomas P. ;
Fisher, Maxine D. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (06) :470-477
[6]   Lifetime Costs of Medical Care After Heart Failure Diagnosis [J].
Dunlay, Shannon M. ;
Shah, Nilay D. ;
Shi, Qian ;
Morlan, Bruce ;
VanHouten, Holly ;
Long, Kirsten Hall ;
Roger, Veronique L. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (01) :68-75
[7]   CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2017 EXECUTIVE SUMMARY [J].
Garber, Alan J. ;
Abrahamson, Martin J. ;
Barzilay, Joshua I. ;
Blonde, Lawrence ;
Bloomgarden, Zachary T. ;
Bush, Michael A. ;
Dagogo-Jack, Samuel ;
DeFronzo, Ralph A. ;
Einhorn, Daniel ;
Fonseca, Vivian A. ;
Garber, Jeffrey R. ;
Garvey, W. Timothy ;
Grunberger, George ;
Handelsman, Yehuda ;
Hirsch, Irl B. ;
Jellinger, Paul S. ;
McGill, Janet B. ;
Mechanick, Jeffrey I. ;
Rosenblit, Paul D. ;
Umpierrez, Guillermo E. .
ENDOCRINE PRACTICE, 2017, 23 (02) :207-238
[8]   Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update [J].
Goldenberg, Ronald ;
Clement, Maureen ;
Hanna, Amir ;
Harper, William ;
Main, Andrea ;
Retnakaran, Ravi ;
Sherifali, Diana ;
Woo, Vincent ;
Yale, Jean-Francois ;
Cheng, Alice Y. Y. .
CANADIAN JOURNAL OF DIABETES, 2016, 40 (03) :193-195
[9]   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].
Haffner, SM ;
Lehto, S ;
Rönnemaa, T ;
Pyörälä, K ;
Laakso, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234
[10]  
Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120